NCT02053753View on ClinicalTrials.gov

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

PHASE1CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy Volunteer
Interventions
DRUG

Denosumab CP4

Denosumab produced by a process referred to as CP4, administered subcutaneously.

DRUG

Denosumab CP2

Denosumab produced by a process referred to as CP2, administered subcutaneously.

Trial Locations (2)

78209

Research Site, San Antonio

90630

Research Site, Cypress

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY